Search

Your search keyword '"Brusamolino, E."' showing total 4 results
Start Over Author "Brusamolino, E." Journal british journal of haematology
4 results on '"Brusamolino, E."'

2. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis

Author

Passamonti, Francesco, Malabarba, L, Orlandi, E, Pascutto, C, Brusamolino, E, Astori, C, Baratè, C, Canevari, A, Corso, A, Bernasconi, P, Cazzola, M, and Lazzarino, M.

Subjects
Adult, Aged, 80 and over, Male, Risk, Chronic myeloproliferative disorders, essential thrombocythaemia, pipobroman, thrombosis, second malignancies, Thrombosis, Middle Aged, Pipobroman, Treatment Outcome, Leukemia, Myeloid, Primary Myelofibrosis, Neoplasms, Humans, Female, Platelet Aggregation Inhibitors, Aged, Follow-Up Studies, Proportional Hazards Models, Thrombocythemia, Essential
Abstract

Essential thrombocythaemia (ET) is a disease associated with an elevated risk of thrombosis. This study evaluated the efficacy and safety of pipobroman (PB) in the long-term control of ET patients who had, at diagnosis, one or more of the following currently known risk factors for thrombosis or haemorrhage (high-risk patients): age60 years, history of thrombosis or haemorrhage, platelets1000 x 10(9)/l. From 1978 to 2000, with a median follow-up of 10 years, 118 previously untreated high-risk ET patients (median age 62 years, range 25-82), were treated with PB at the starting dose of 0.8-1 mg/kg/d. All patients reached a platelet count600 x 10(9)/l and 91% achieved a platelet count400 x 10(9)/l. During follow-up, 13 patients had thrombosis, with a 10-year cumulative risk of 14%. Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively. Actuarial survival at 20 years was 64% and the standardized mortality ratio was 1.1 (95% CI: 0.7-1.7), not statistically different from the general population (P = 0.54). Age was associated with a higher risk of death (P = 0.00009) and thrombosis (P = 0.003). The duration of PB treatment did not correlate with the occurrence of second malignancies. This study, with a median follow-up of 10 years, demonstrates that pipobroman is effective and well tolerated. The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET.

Published
2002

3. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.

Author

Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, and Santoro A

Subjects
Adult, Bendamustine Hydrochloride, Drug Evaluation methods, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Recurrence, Retrospective Studies, Salvage Therapy methods, Treatment Failure, Treatment Outcome, Young Adult, Antineoplastic Agents, Alkylating therapeutic use, Hematopoietic Stem Cell Transplantation methods, Hodgkin Disease drug therapy, Nitrogen Mustard Compounds therapeutic use
Published
2014
Full Text
View/download PDF

4. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.

Author

Bernasconi C, Alessandrino EP, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A, Castelli G, Brusamolino E, Pagnucco G, and Castagnola C

Subjects
Acute Disease, Adult, Aged, Chromosome Aberrations, Cytarabine administration & dosage, Disease-Free Survival, Etoposide administration & dosage, Female, Follow-Up Studies, Gene Rearrangement, Humans, Idarubicin administration & dosage, Leukemia, Myeloid genetics, Male, Middle Aged, Myelodysplastic Syndromes genetics, Neutropenia therapy, Recurrence, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid therapy, Myelodysplastic Syndromes therapy
Abstract

One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12h i.v. for 5d, Ara-C 120 mg/ m2/12h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 microg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+ G-CSF patients had a significantly shorter duration of neutropenia (8 nu 16d) with a lower incidence of infections and significantly better responses (CR+PR: 74% v 52%, P<0.05). 40 patients entered CR: 17 with CT and 2 3 with CT+G-CSF. Responders underwent two consolidation courses with the same CT, followed by high-dose Ara-C (2 g/m2 every 12h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4 5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results